John Chiplin
Non-Executive Director
Health Care
Sienna Cancer Diagnostics
Australia
Biography
John Chiplin B.Pharm PhD is a very experienced healthcare executive and brings considerable capital markets experience to the Sienna Board. His most recent executive position was CEO of Polynoma LLC, a US based cancer immunotherapy company, and he was formerly the founding CEO of ASX listed Arana Therapeutics Ltd prior to that company’s acquisition by Cephalon (now Teva). Before his appointment at Arana Dr Chiplin was head of the UK’s $300M ITI Life Science investment fund. He is currently a Non-Executive Director of ASX listed biotechnology companies Benitec Biopharma (ASX:BLT) and Cynata Therapeutics (ASX:CYP), as well as Adalta Ltd (ASX:1AD), and Chairman of UK AIM listed company Scancell Holdings Plc (AIM:SCLP). Dr Chiplin is also the founder and Managing Director of Newstar Ventures, an early stage investment fund.
Research Interest
Businnes Growth
